8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
A critical appraisal of the Krystal 2010 six-month zolpidem extended-release RCT, covering enrollment biases, generalizability gaps, statistical caveats, industry funding, and what post-publication commentary revealed.
A deep-dive into the design choices behind the Krystal 2010 zolpidem extended-release trial, the longest-duration zolpidem efficacy RCT, and what those choices mean for interpreting the results.
Economic analysis of the 6-month Krystal zolpidem extended-release RCT: cost per QALY estimates, payer coverage patterns, list-price versus net-price realities, and patient-level value calculations.
Deep dive into the 6-month Krystal zolpidem ER trial's durability data, regression-to-mean considerations, late-emerging safety signals, and long-term outcome lessons from the longest controlled zolpidem efficacy study.
Detailed breakdown of the Krystal 2010 zolpidem extended-release RCT results including effect sizes, secondary endpoints, time-course patterns, and response distribution over 6 months.
Deep-dive into pre-specified and post-hoc subgroup analyses from the 6-month Krystal zolpidem ER trial, examining differential efficacy by age, sex, BMI, and baseline severity.
A deep-dive plain-English breakdown of the Krystal 2010 Sleep trial: methodology, enrollment criteria, endpoints, results tables, limitations, and what the 6-month zolpidem ER data mean for prescribers today.
A deep-dive into the clinical-practice implications of the Krystal 2010 zolpidem extended-release RCT: which prescribing patterns should shift, where the trial's population limits generalizability, and what six months of efficacy data actually means at the bedside.